Foamix Pharmaceuticals Ltd (FOMX) Downgraded by Zacks Investment Research to Hold
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
Separately, Credit Suisse Group AG began coverage on shares of Foamix Pharmaceuticals in a report on Wednesday, February 15th. They set an “outperform” rating and a $22.00 target price for the company.
Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) traded up 0.21% during midday trading on Tuesday, hitting $4.83. 99,615 shares of the company’s stock were exchanged. Foamix Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $11.27. The firm’s market cap is $179.52 million. The company has a 50-day moving average of $4.55 and a 200-day moving average of $8.44.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Tuesday, February 21st. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. Foamix Pharmaceuticals had a negative return on equity of 22.55% and a negative net margin of 554.14%. The business had revenue of $1.49 million for the quarter. Equities research analysts expect that Foamix Pharmaceuticals will post ($1.38) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Foamix Pharmaceuticals Ltd (FOMX) Downgraded by Zacks Investment Research to Hold” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/05/16/foamix-pharmaceuticals-ltd-fomx-downgraded-by-zacks-investment-research-to-hold.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in FOMX. Baird Financial Group Inc. acquired a new position in shares of Foamix Pharmaceuticals during the first quarter valued at approximately $188,000. Trexquant Investment LP acquired a new position in shares of Foamix Pharmaceuticals during the fourth quarter valued at approximately $244,000. Renaissance Technologies LLC acquired a new position in shares of Foamix Pharmaceuticals during the first quarter valued at approximately $307,000. Emory University acquired a new position in shares of Foamix Pharmaceuticals during the first quarter valued at approximately $1,007,000. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Foamix Pharmaceuticals by 0.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 123,235 shares of the specialty pharmaceutical company’s stock valued at $1,368,000 after buying an additional 1,059 shares during the last quarter. Institutional investors and hedge funds own 64.94% of the company’s stock.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Foamix Pharmaceuticals Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd and related companies with MarketBeat.com's FREE daily email newsletter.